Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Guardant Health ( (GH) ) is now available.
At the annual meeting of stockholders held on June 18, 2025, Guardant Health, Inc. elected all nominees for its board of directors, including Vijaya Gadde, Roberto Mignone, Myrtle Potter, and Musa Tariq. Additionally, the stockholders approved the selection of Deloitte & Touche LLP as the independent registered public accounting firm for 2025 and endorsed the compensation of the company’s named executive officers.
The most recent analyst rating on (GH) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Guardant Health stock, see the GH Stock Forecast page.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
Guardant Health’s overall stock score is primarily impacted by its financial performance challenges, including high leverage and cash flow issues, despite strong revenue growth. Positive technical indicators and a favorable earnings call provide some support, but valuation concerns remain due to ongoing losses.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
Guardant Health, Inc. operates in the healthcare industry, focusing on developing and commercializing blood tests for early cancer detection and treatment guidance.
Average Trading Volume: 2,198,345
Technical Sentiment Signal: Buy
Current Market Cap: $6.27B
For detailed information about GH stock, go to TipRanks’ Stock Analysis page.